Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.52 |
| ▸ | CTSK | P43235 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | PTPRA | P18433 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | NPR3 | P17342 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18239928 | 0.89 | CTSS (0.53) | CTSSCTSKLMNAKMT2ASCN9A | |
| SCHEMBL20208717 | 0.89 | CTSS (0.53) | CTSSCTSKLMNAKMT2ASCN9A | |
| SCHEMBL28576290 | 0.88 | LMNA (0.59) | CTSSCTSKLMNAKMT2ASCN9A | |
| SCHEMBL29635622 | 0.87 | CTSS (0.51) | CTSSCTSKLMNAKMT2ASCN9A | |
| SCHEMBL29635623 | 0.87 | CTSS (0.51) | CTSSCTSKLMNAKMT2ASCN9A | |
| SCHEMBL29635621 | 0.87 | CTSS (0.51) | CTSSCTSKLMNAKMT2ASCN9A | |
| SCHEMBL22567356 | 0.85 | CYP3A4 (0.49) | CTSSCTSKLMNAKMT2ANPR3 | |
| SCHEMBL24506756 | 0.85 | CYP3A4 (0.49) | CTSSCTSKLMNAKMT2ANPR3 | |
| SCHEMBL20202782 | 0.81 | CTSS (0.54) | CTSSCTSKSCN9ACTSLCTSB | |
| SCHEMBL24101047 | 0.81 | LMNA (0.49) | CTSSCTSKLMNAKMT2ANPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220184021-A1 | NOVEL FORMULATIONS COMPRISING MELFLUFEN | ONCOPEPTIDES AB (SE) | 2022-06-16 | — | — | US | disclosed |
| US-20210388024-A1 | COMPOUNDS CONTAINING DEUTERIUM | ONCOPEPTIDES AB (SE) | 2021-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210388024-A1 | COMPOUNDS CONTAINING DEUTERIUM | DHX30, H1-10, REN | CTSS 1722/4885CTSK 1337/4885LMNA 3001/4885 |
| US-20220184021-A1 | NOVEL FORMULATIONS COMPRISING MELFLUFEN | F12, FGF2, MC3R | CTSS 3982/4885CTSK 3527/4885LMNA 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.